SOLX Gold Shunt Cleared in Canada for Surgical Treatment of Glaucoma
August 12, 2009
Submit Comments
SOLX has announced that the company has received clearance from Health Canada for the use of the gold shunt in the surgical treatment of glaucoma.
In a prospective, open label study with 12 months of follow-up using SOLX’s GMS+ Gold Shunt, IOP was reduced 45.6% from the Best Medicated Baseline in patients that had failed maximum medical therapy and at least one prior surgical intervention.
The SOLX Gold Shunt is biocompatible, 99.95% pure gold and provides a pathway for the flow of aqueous humor from the anterior chamber of the eye to the suprachoroidal space. This shunt reduces IOP without the formation of a bleb.
Read the release.
Comments (0)
Trackbacks
Print this post
Filed in Glaucoma, Industry News, New Technologies, Optic Nerve
You might also enjoy...
- Implantation of SOLX Gold Shunt into Supraciliary Space Controls Intraocular Pressure in Glaucoma Patients
- Patients With Glaucoma Sought for Clinical Trial Underway at Yale School of Medicine to Establish Ability of SOLX Gold Shunt to Reduce IOP
- Is ExPRESS Shunt Just Hype?
- Will New Carbon Material Revolutionize Surgical Treatment of Glaucoma?
- Is Canaloplasty Worthwhile?
Comments
Jump down to form below to submit your own comments
